Related Experiment Video
Updated: Jun 28, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Targeting the GLP-1 receptor pathways for dual management of obesity and depression
Ruchi Keswani1, Shvetank Bhatt1
1School of Health Sciences and Technology, Dr Vishwanath Karad MIT World Peace University, Pune, Maharashtra, India.
Abstract:
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs), initially developed for the treatment of diabetes mellitus, are now widely used in obesity management. Obesity and depression are interconnected and share common biological pathways, including inflammation, oxidative stress, neurotransmitter imbalance, mitochondrial dysfunction, adipocytokine alterations, as well as gut-brain and HPA-axis dysregulation. These mechanisms are mediated by the signaling pathways that involve the GLP-1 receptor and provide a therapeutic target in comorbid disorders. GLP-1RAs have an impact on glycemic levels, weight reduction, insulin sensitivity, appetite and satiety control. Recent studies also highlight their neuroprotective effects, including modulation of dopaminergic pathways, enhanced hippocampal neurogenesis and neuroinflammation reduction. Hence, this review focuses on the therapeutic potential of using GLP-1 receptor pathways in the dual treatment of obesity and depression.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Antidepressant Drugs: MAOIs and Other Agents
Regulation of Food Intake
G-protein Coupled Receptors
Dipeptidyl Peptidase 4 Inhibitors

